BioRestorative Therapies, Inc.BRTX
Price (close)
$2.55
Market cap
$3.5M
P/E
—
Revenue (TTM)
$357,870
Net income
-$11.1M
Dividend yield
—
1-year total return
75.9%
Net margin
-3089.5%
Revenue growth
-8.5%
Debt / equity
—
What BioRestorative Therapies, Inc. does.
were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to
“BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we
are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100 .
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $77,000 | $46,000 | $119,800 | $145,800 | $401,000 | $359,700 |
| Net income | -$11.3M | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M |
| Free cash flow | — | -$3.4M | -$6.2M | -$6.6M | -$8.3M | -$10.9M |
More on BRTX.
- BioRestorative Therapies, Inc. summary
- BioRestorative Therapies, Inc. financial statements
- BioRestorative Therapies, Inc. key metrics
- BioRestorative Therapies, Inc. health scores and style box
- BioRestorative Therapies, Inc. earnings
- BioRestorative Therapies, Inc. dividends
- BioRestorative Therapies, Inc. valuation
- BioRestorative Therapies, Inc. ownership and insiders
- BioRestorative Therapies, Inc. peers
Figures from BioRestorative Therapies, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.